or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    APLT B -0.32 24.20
    PAGP A 1.36 21.27
    PHAT F 6.53 8.70
    AKRO C 0.05 6.84
    MDGL C 1.51 5.87
    RNA C -0.54 5.13
    ARDX F 2.24 3.93
    TSAT D 8.70 1.83
    SNDX F -3.26 1.47
    KYMR D -2.02 1.37
    KURA F -36.90 1.30
    ACHV F -0.81 0.99
    ATHA D 0.05 0.62
    CMPS F -2.58 0.56
    VRCA F 3.91 0.27

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Cancer Medicine Biotechnology Medication Metabolic Disease Solid Tumors Benzamides Breast Cancer Clinical Medicine Clinical Trial Gastrointestinal Life Sciences Pharmaceutical Products Thyroid Treatment Of Breast Cancer Acid Acute Leukemia Alcohol Antineoplastic Drugs
    Industries: Biotechnology Communication Equipment Medical Care Facilities Oil & Gas Midstream

    Recent News for Simplify Exchange Traded Funds Simplify Propel Opportunities ETF & its Holdings

    Date Stock Title
    Nov 21 KURA Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
    Nov 21 KURA Kura Oncology partners Kyowa Kirin to advance AML treatment
    Nov 20 KURA Kura stock slides 17% on Kyowa Kirin deal for ziftomenib
    Nov 20 KURA Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
    Nov 20 MDGL Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra
    Nov 20 ARDX Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
    Nov 19 ARDX High Growth Tech Stocks To Explore In November 2024
    Nov 19 PHAT Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know
    Nov 18 AKRO Akero a new buy at Citi on liver disease asset
    Nov 18 ARDX US Penny Stocks To Monitor In November 2024
    Nov 18 SNDX Syndax secures FDA OK for new kind of leukemia drug
    Nov 18 SNDX FDA approves Syndax’s Revuforj to treat leukaemia
    Nov 18 MDGL The first MASH drug could open the door for others — including GLP-1s
    Nov 15 SNDX Syndax wins FDA approval for leukemia drug revumenib
    Nov 15 SNDX Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
    Nov 15 MDGL Madrigal Pharmaceuticals gains amid takeover speculation
    Nov 15 AKRO Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
    Nov 15 CMPS RFK and the 'MAHA Trade': Vaccine makers down, psychedelic shares up
    Nov 15 MDGL John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
    Nov 14 MDGL Paulson & Co. exits AngloGold Ashanti, boosts Madrigal Pharma among Q3 moves
    The fund is an actively managed exchange-traded fund. The Sub-Adviser concentrates the fund's investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The fund is non-diversified.
    Exchange Traded Funds Bond Biotechnology Stock Fund Mutual Fund Pharmaceutical Healthcare Technology Life Science Tools
    Back to the Main SURI Page...